Stay updated with breaking news from Celcuity Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients
Brokerages predict that Celcuity Inc. (NASDAQ:CELC – Get Rating) will post earnings of ($0.51) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Celcuity’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.45). Celcuity posted earnings of ($0.25) per share in the same quarter […]
Celcuity Inc. (NASDAQ:CELC – Get Rating) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokerages […]
Celcuity (NASDAQ:CELC – Get Rating) issued its earnings results on Wednesday. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07), Fidelity Earnings reports. During the same quarter last year, the business posted ($0.25) earnings per share. Celcuity stock traded up $0.39 during mid-day trading on Friday, hitting $8.35. […]
Finalized pivotal Phase 3 trial design following formal meetings with FDAReceived FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancerPresented updated Phase 1b data during